Zedira

Executive Summary

Zedira is a privately held, clinical-stage biopharmaceutical company based in Darmstadt, Germany, with a unique dual business model encompassing specialty research reagents and first-in-class small-molecule therapeutics targeting transglutaminases. The company's lead drug candidate, ZED1227, is an oral tissue transglutaminase 2 (TG2) inhibitor that has demonstrated clinical proof-of-concept in celiac disease, representing a potential first-in-disease therapy. With a robust portfolio of diagnostic tools and a therapeutic pipeline addressing dysregulated transglutaminases in celiac disease, fibrotic disorders, and other indications, Zedira is well-positioned to capitalize on its expertise in transglutaminase biology. The company's reagent business provides a steady revenue stream and strategic synergies with its drug development efforts, reducing burn rate and enhancing long-term viability. Zedira is poised for significant value creation as it advances ZED1227 toward late-stage clinical development. The company's strong proof-of-concept data in celiac disease, combined with a growing pipeline of follow-on candidates, underpins a favorable risk-reward profile. Near-term catalysts include the initiation of Phase 2b/3 trials for ZED1227 in celiac disease, potential strategic partnerships for commercialization, and preclinical data readouts for new TG inhibitors in other fibrotic or inflammatory indications. With a disciplined approach and a validated platform, Zedira represents an attractive opportunity in the rare disease and precision medicine space.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 2b/3 trial for ZED1227 in celiac disease85% success
• H2 2026Strategic partnership for ZED1227 commercialization in major markets65% success
• Q1 2027Preclinical proof-of-concept data for novel TG6 inhibitor in fibrotic disease50% success